|
See related Cerezyme inj information |
|
|
|
Manufacturer |
Genzyme |
|
Distributor |
Hong Kong: DKSH |
|
Contents |
Imiglucerase |
|
Indications |
Long-term enzyme replacement therapy for ped & adult patients w/ a confirmed diagnosis of type 1 Gaucher disease that results in anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly. |
|
Dosage |
By IV infusion over 1-2 hr. Initially, dosage range: 2.5 u/kg 3 times a wk to 60 u/kg once every 2 wk. Individualised dosage adjustments. |
|
Special Precautions |
Monitor periodically for IgG antibody formation during the 1st yr. Anaphylactoid reactions. Development of antibody or hypersensitivity to Ceredase. Pregnancy & lactation. |
|
Adverse Drug Reactions |
Discomfort, pruritus, burning, swelling or sterile abscess at the site of venipuncture. Hypersensitivity & anaphylactoid reactions. Nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache & tachycardia.
View ADR Monitoring Form |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
ATC Classification |
A16AB02 - imiglucerase ; Belongs to the class of enzymes. Used in treatment of alimentary tract and metabolism problems. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Cerezyme injection |
|
|
|
Manufacturer: |
Genzyme |
|
Distributor: |
Hong Kong: DKSH
|
|
|
|
